ClinicalTrials.gg
WithdrawnNCT06703333OPTIONUpdated Aug 6, 2026

Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study)

An Early Phase 1 interventional study of Extracorporeal photopheresis (ECP) in Stiff Person Syndrome, sponsored by Yandy Marx Castillo Aleman. Withdrawn at 1 site in United Arab Emirates. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Yandy Marx Castillo Aleman · Early Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Unavailability of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

OPTION study is a pilot, open-label, prospective, and multicentric clinical trial involving outpatients with a diagnosis of classical stiff person syndrome (SPS), whereas extracorporeal photopheresis (ECP) is the investigational treatment. The study will be conducted at the Specialized Rehabilitation Hospital/Capital Health and Yas Clinic Khalifa City (YCKC) Hospital (managed by Abu Dhabi Stem Cells Center -ADSCC), clinical sites responsible for patient assessment and inclusion, and follow-up consultations, according to the approved Protocol, while YCKC will be the site in which patients will undergo the investigational intervention (ECP).

Read the detailed description

The study complies with the current Good Clinical Practices (GCPs) and follows the principles of the Declaration of Helsinki. The primary objective is the safety profile assessment of the investigational intervention, to be assessed by ECP procedure tolerability, the incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0), and the World Health Organization - Uppsala Monitoring Center (WHO-UMC) causality assessment system. The ECP preliminary efficacy assessment, as a secondary objective, will be assessed by the proportion of SPS subjects who are treatment responders, defined as ≥ 2 points reduction in the Distribution of Stiffness Index (DSI) AND ≥ 1 point reduction in Heightened Sensitivity Score (HSS).

02

Conditions studied

  • Stiff Person Syndrome

Browse trials for

Keywords

  • Stiff Person Syndrome
  • Extracorporeal Photopheresis
  • ECP
  • Immunoregulation
03

In context

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Lead sponsor

This is the only study on the registry with Yandy Marx Castillo Aleman as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of classical SPS with serum and CSF anti-GAD antibodies.
  • Age ≥ 18 ≤ 75 years.
  • Weight ≥ 50 kg.
  • Hematocrit ≥ 30 % (with or without transfusion support).
  • count ≥ 100 x 10\^3/uL (with or without transfusion support).
  • Willingness to use at least one reliable method of (e.g., abstinence, oral contraceptives, intrauterine devices, barrier method with spermicide, or surgical sterilization) throughout the study for all men and women of .
  • Willingness to participate in all study tests, visits, and procedures (including ECP), as outlined in the .
  • Adequate peripheral venous access to initiate ECP therapy.
  • The patient agrees to participate in the trial and signs the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Progressive encephalomyelitis with rigidity and myoclonus (PERM).
  • Paraneoplastic variants of SPS.
  • Concurrent diagnosis of a neurological condition that would interfere with the assessment of SPS.
  • Women who are pregnant and/or lactating.
  • Absolute medical to receive ECP.

    • or allergy to psoralen (methoxalen).
    • Hypersensitivity or allergy to heparin.
    • Previous history of heparin-induced thrombocytopenia.
    • Aphakia or photosensitive disease (systemic lupus erythematosus, porphyrias, etc.).
  • Laboratory evidence of any of the following:

    • Mononuclear cell (MNC) count \<2.0 x 10\^3 cells/uL.
    • Serum transaminase levels > x 2 UNL.
    • Estimated (eGFR) \<60 mL/min/1.73 m2.
  • Evidence of known infection with (HIV) or .
  • Uncontrolled infection requiring treatment at study entry.
  • Use of any drug/treatment at the time of enrollment or within the previous 60 days, or five elimination half-lives, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
  • Previous history of skin cancer, leukemia / lymphoma / myeloma, or bone marrow transplant.
  • Any other disease or condition which, in the opinion of the investigator, could interfere with participation according to the study Protocol, or with the ability of the patients to cooperate and comply with study procedures.
  • Inability to provide .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Experimental arm

    Single group assignment in which SPS patients will receive ECP as an add-on therapy on the following schedule: * Months 1-3: One ECP cycle (two consecutive days) every other week for 3 months (12 procedures). * Months 4-6: One ECP cycle every month for 3 months (6 procedures).

    Combination Product: Extracorporeal photopheresis (ECP)

Interventions

  • Combination productExtracorporeal photopheresis (ECP)

    * Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures). * Months 4-6: One ECP cycle every month for 3 months (6 procedures). * Total: 18 procedures (within 6 months \~24 weeks).

    Also known as: Extracorporeal photochemotherapy

06

What researchers measure

Primary outcomes

  1. Tolerability to ECP procedures

    Proportion of patients tolerating the ECP procedures reaching the cycles' goal.

    Time frame: Weeks 0-24

  2. Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) assessed by CTCAE v5.0.

    Proportion of patients referring TEAEs, AESIs, and SAEs.

    Time frame: Weeks 0-52

  3. Tolerability to TEAEs, AESIs, and SAEs

    Proportion of patients tolerating TEAEs, AESIs, and SAEs, and finalizing the planned study.

    Time frame: Weeks 0-52

Secondary outcomes

  1. Proportion of subjects with clinical improvement

    Proportion of SPS subjects who are treatment responders, defined as: * ≥ 2 points reduction in the Distribution of Stiffness Index (DSI), and * ≥ 1 point reduction in Heightened Sensitivity Score (HSS). Marker for efficacy of the investigational intervention. 1. DSI: Scores on this index range from 0 to 6 and reflect the extent of stiffness; with one point being given for stiffness in each of the following areas: lower trunk, upper trunk, legs, arms, face, and abdomen. Lower scores indicate less stiffness. 2. HSS: Scores range from 1 to 7 based on response; one point being given for each source of or type of spasm, as follows: unexpected noises, visual stimuli, somatosensory stimuli, voluntary activities, emotional upset or stress, no specific stimuli, and nocturnal spasms. Lower scores indicate less frequent spasms.

    Time frame: Baseline, months 3, 6, 9, and 12

07

Study locations

1 site
  • Abu Dhabi Stem Cells Center
    Abu Dhabi, 4600, United Arab Emirates
08

References and documents

Publications

  • Castillo-Aleman YM, Krystkowiak PC. Extracorporeal photopheresis in stiff person syndrome. Front Immunol. 2024 Dec 16;15:1519032. doi: 10.3389/fimmu.2024.1519032. eCollection 2024. No abstract available. PubMed 39759515 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 25, 2024
StartEst.
Aug 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703333
Lead sponsor
Yandy Marx Castillo Aleman
Responsible party
Yandy Marx Castillo Aleman (Specialist Immunologist, Abu Dhabi Stem Cells Center) — Sponsor-investigator
First posted
Nov 25, 2024
Start date
Aug 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion